Puma Biotechnology Inc Stock Price, News & Analysis

Puma Biotechnology (NASDAQ: PBYI) announced its participation in Cowen's 43rd Annual Health Care Conference from March 6-8, 2023, at the Boston Marriott Copley Place. Alan H. Auerbach, the company’s Chairman and CEO, will join a Breast and Lung Cancer Panel Discussion on March 7 at 10:30 a.m. ET. A live webcast will be available at this link, with a replay accessible for 30 days on Puma’s website. Puma is known for its innovative cancer care solutions, including NERLYNX (neratinib), which is FDA-approved for various HER2-positive breast cancer treatments.

Puma Biotechnology (NASDAQ: PBYI) will hold a conference call on March 2, 2023, at 1:30 p.m. PST to discuss its fourth quarter and full year 2022 financial results. Investors can join the call by dialing 1-877-709-8150 for domestic or 1-201-689-8354 for international access. The call will also feature a live webcast available on the company’s website, which will be archived for 90 days.

Puma, focused on innovative cancer care solutions, markets NERLYNX (neratinib), approved by the FDA in 2017. They have also licensed alisertib for small cell lung cancer and breast cancer treatment.

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on February 6, 2023 that its Compensation Committee approved the grant of inducement restricted stock unit awards covering 34,163 shares to four new non-executive employees. The awards are part of Puma's 2017 Employment Inducement Incentive Award Plan and will vest over a three-year period, promoting employee retention. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to bolster the company’s biopharmaceutical development efforts.

Puma Biotechnology (NASDAQ: PBYI) announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for Breast Cancer to include neratinib (NERLYNX^®) as a category 2B therapy for ER+/HER2- or ER-/HER2- metastatic breast cancer with activating HER2 mutations. This update highlights neratinib's use in combination with fulvestrant and trastuzumab. The decision is based on results from the Phase 2 SUMMIT and MutHER trials. Additionally, the NCCN has included a dose escalation schedule for neratinib for better tolerability. The update reflects growing recognition of neratinib's potential in treating advanced breast cancer.

Puma Biotechnology (NASDAQ: PBYI) will present an overview of its operations at the B. Riley Securities’ 3rd Annual Oncology Conference on January 19 at 11:00 a.m. PST. The presentation by CEO Alan H. Auerbach will be accessible via live webcast at this link.

Puma focuses on developing innovative cancer treatments, including NERLYNX® for HER2-positive breast cancer. Additionally, they are advancing alisertib for small cell lung cancer and breast cancer after securing a license in September 2022.

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on January 10, 2023, the grant of 22,250 inducement restricted stock unit awards to four new non-executive employees. These awards, approved by the Compensation Committee, will vest over three years, with the first third vesting one year after the commencement date for each employee. This initiative aims to attract talent under Puma's 2017 Employment Inducement Incentive Award Plan. Puma focuses on developing innovative cancer treatments, including NERLYNX® for breast cancer and alisertib for small cell lung cancer.

Puma Biotechnology (NASDAQ: PBYI) announced an update regarding its corporate presentation, which will be discussed by CEO Alan H. Auerbach starting January 9, 2023. The presentation includes a preliminary estimate of approximately 3,323 NERLYNX® bottles sold in the U.S. during Q4 2022. This figure is subject to change pending the completion of standard closing procedures. NERLYNX® is used for treating HER2-overexpressed breast cancer and received FDA approval for various treatment regimens. For further details, the updated slides will be available on Puma’s investor website.

Puma Biotechnology, Inc. (NASDAQ: PBYI) presented updated results from the TBCRC Trial 022 at the 2022 San Antonio Breast Cancer Symposium. This Phase II study assessed the efficacy of neratinib plus T-DM1 in HER2-positive breast cancer brain metastases. Results showed CNS Objective Response Rates of 33.3% in cohort 4A, 29.4% in cohort 4B, and 28.6% in cohort 4C. Neuro-oncological activity suggests neratinib may reverse T-DM1 resistance. Diarrhea was the most common adverse effect. The findings support neratinib-based combinations for treating HER2-positive brain metastases.

Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for three new non-executive employees on December 3, 2022. The awards cover 20,625 shares of common stock and will vest over three years, starting December 1, 2022. This move aligns with Puma’s 2017 Employment Inducement Incentive Award Plan, designed to attract new talent. Puma is focused on advancing cancer care through products like NERLYNX® (neratinib), used in various breast cancer treatments, and is developing alisertib for small cell lung cancer and breast cancer.